Switzerland’s Novartis aims to become a «boutique drugmaker». It’s opened negotiations on voluntary redundancies at it looks to downsize its salesforce in Onco-hematology in Argentina. It aims to reduce a division of 25 medical sales representatives by 36%.
Multinational drugmakers are steadily refining their portfolios to specialise in increasingly sophisticated niches.
Following such a strategy, Switzerland’s Novartis is adjusting the structure of its Onco-hematology team in Argentina, Pharmabiz has learned.
Under the command of its Mexican general manager Monique Clúa, the local unit has activated a plan for voluntary redundancies to reduce its staff in the country.
According to reliable sources, Pharmabiz hears that the company has called in 36% of its reps in Oncology and hematology, which comprise 25 medical salespeople. It’s offering a double compensation based on 67% of gross salary in line with a legal decision in Argentina this year.
The move is in tune with the multinational’s new focus as it aims to become a «boutique drugmaker» – a «laboratory boutique«, as Clúa described the strategy to local staff. The company training more of its artillery at the increasingly important area of gene therapies. Novartis’s Zolgensma is expected to compete with Spinraza. See article in Spanish.
